

Appendix 1 (as supplied by the authors): Supplementary tables

Supplementary Table A1: Patient characteristics and auxological data at baseline for growth hormone-treated children, by primary diagnostic category (all patients with known diagnosis and baseline height standard deviation score available)

a) Canada

	OGHD	IGHD	Turner syndrome	Idiopathic short stature	Small for gestational age
Number of patients	n=310	n=125	n=148	n=33	n=17
Males (%)	68.1%	69.6%	–	84.8%	41.2%
Age (years)	7.2 (6.7 to 7.7)	10.0 (9.1 to 10.8)	9.3 (8.7 to 9.8)	12.2 (11.1 to 13.2)	6.6 (4.6 to 8.5)
Height SDS	–2.27 (–2.44 to –2.10)	–2.67 (–2.88 to –2.46)	–2.93 (–3.05 to –2.80)	–2.67 (–2.98 to –2.37)	–3.81 (–4.44 to –3.18)
Height velocity (cm/year)	5.18 (4.61 to 5.75)	4.80 (4.27 to 5.33)	4.61 (4.19 to 5.03)	4.91 (4.26 to 5.56)	7.77 (5.74 to 9.81)
Height velocity SDS	–1.79 (–2.03 to –1.54)	–1.29 (–1.58 to –1.01)	–1.20 (–1.56 to –0.83)	–0.35 (–1.16 to 0.46)	0.03 (–1.15 to 1.20)
Target height SDS	0.04 (–0.07 to 0.14)	–0.41 (–0.58 to –0.24)	–0.03 (–0.17 to 0.10)	–0.57 (–0.84 to –0.30)	–0.28 (–0.55 to 0.00)
Target height SDS deficit ^a	–2.45 (–2.65 to –2.26)	–2.27 (–2.53 to –2.00)	–2.92 (–3.07 to –2.77)	–2.08 (–2.43 to –1.74)	–3.44 (–4.10 to –2.79)
Stimulated peak GH (µg/l)	3.3 (2.7 to 4.0)	4.6 (3.9 to 5.3)	NA	24.1 (17.8 to 30.5)	NA
GH dose (mg/kg/week)	0.18 (0.18 to 0.19)	0.19 (0.18 to 0.20)	0.29 (0.28 to 0.29)	0.23 (0.21 to 0.25)	0.23 0.20 to 0.26)

b) All countries combined (including Canada)

	OGHD	IGHD	Turner syndrome	Idiopathic short stature	Small for gestational age
Number of patients	n=2508	n=10189	n=1712	n=2657	n=1209
Males (%)	65.5%	67.6%	–	71.9%	54.7%
Age (years)	8.2 (8.0 to 8.3)	10.1 (10.0 to 10.2)	8.8 (8.6 to 9.0)	11.3 (11.1 to 11.4)	8.2 (8.0 to 8.4)
Height SDS	–2.42 (–2.48 to –2.36)	–2.41 (–2.43 to –2.40)	–2.60 (–2.65 to –2.56)	–2.41 (–2.44 to –2.38)	–2.68 (–2.73 to –2.63)
Height velocity (cm/year)	4.72 (4.55 to 4.90)	4.71 (4.66 to 4.77)	4.99 (4.82 to 5.16)	4.82 (4.71 to 4.93)	5.42 (5.24 to 5.60)

Height velocity SDS	-1.61 (-1.72 to -1.51)	-1.03 (-1.07 to -0.98)	-1.14 (-1.26 to -1.02)	-0.77 (-0.86 to -0.69)	-0.84 (-0.97 to -0.72)
Target height SDS	-0.06 (-0.10 to -0.02)	-0.55 (-0.57 to -0.53)	0.02 (-0.03 to 0.06)	-0.55 (-0.58 to -0.52)	-0.62 (-0.67 to -0.57)
Target height SDS deficit ^a	-2.43 (-2.49 to -2.36)	-1.86 (-1.88 to -1.84)	-2.61 (-2.67 to -2.56)	-1.86 (-1.90 to -1.82)	-2.06 (-2.13 to -1.99)
Stimulated peak GH (µg/l)	4.2 (4.0 to 4.4)	8.2 (8.0 to 8.3)	NA	16.8 (16.4 to 17.2)	NA
GH dose (mg/kg/week)	0.23 (0.22 to 0.23)	0.25 (0.25 to 0.25)	0.32 (0.31 to 0.32)	0.33 (0.33 to 0.34)	0.28 (0.28 to 0.29)

Note: GH = growth hormone, IGHD = idiopathic growth hormone deficiency, NA = data available for <60% of patients, OGHD = organic growth hormone deficiency,

SDS = standard deviation score.

Data show mean (95% confidence intervals); patient numbers are for those with height SDS at baseline and 1-year, but not all patients had all other information.

^aHeight SDS minus target height SDS.

Supplementary Table A2: Cause of death and characteristics of growth hormone-treated patients who died during study, grouped by primary diagnosis of growth disorder

Diagnostic group Primary diagnosis	Sex	Age (years)	Time from GH start (years)	GH duration (years)	Cause of death	Probably or possibly related
OGHD						
Acute lymphoblastic leukemia	Male	12	4.8	4.3	Cerebral neuroblastoma	No
Astrocytoma	Male	9	3.3	0.3	Astrocytoma recurrence	No
Astrocytoma	Male	15	6.4	6.2	Astrocytoma recurrence	Yes
Medulloblastoma	Male	11	3.7	3.3	Medulloblastoma recurrence	Yes
Medulloblastoma	Male	12	1.4	1.5	Medulloblastoma recurrence	Yes
Hypopituitarism	Male	0.6	0.2	0.2	Cardiorespiratory arrest	No
Septo-optic dysplasia and hypopituitarism	Male	1.9	1.5	1.5	Gastrointestinal hemorrhage	No
Turner syndrome						
Turner syndrome	Female	16	9.8	5.5	Metastatic Ewing sarcoma	No
Other						
Chronic renal insufficiency and Down syndrome	Male	3	1.7	1.7	Cardiorespiratory arrest	No
Duchenne muscular dystrophy	Male	15	0.2	0.2	Cardiac arrest	No
Pseudohypoparathyroidism and panhypopituitarism	Male	11	10.7	10.7	Pneumonia	No

Note: GH = growth hormone, OGHD = organic growth hormone deficiency.